Mechano-Therapeutics Platform
Fibro-inflammatory diseases (e.g., IPF, IBD/Crohn's, RA-ILD, Scleroderma) and Cancer
PreclinicalActive
Key Facts
Indication
Fibro-inflammatory diseases (e.g., IPF, IBD/Crohn's, RA-ILD, Scleroderma) and Cancer
Phase
Preclinical
Status
Active
Company
About Zenon Biotech
Zenon Biotech is pioneering a novel therapeutic approach by targeting mechano-sensors—cellular receptors that respond to pathological tissue stiffness—in fibrotic diseases and cancer. Founded by Harvard scientist-entrepreneur David Lagares, the company is built on world-leading expertise in mechanobiology and is in the preclinical stage of developing its drug pipeline. Its platform aims to address significant unmet needs in diseases like IPF and Crohn's, where current anti-inflammatory or anti-fibrotic therapies are inadequate, positioning Zenon at the forefront of a new drug class termed 'mechano-therapeutics'.
View full company profile